Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
Top Cited Papers
Open Access
- 1 April 2011
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 377 (9773) , 1256-1263
- https://doi.org/10.1016/s0140-6736(11)60136-0
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases
This publication has 30 references indexed in Scilit:
- Enzyme-Linked Immunosorbent Assay for Measurement of Cytomegalovirus Glycoprotein B Antibody in SerumClinical and Vaccine Immunology, 2010
- Cytomegalovirus Reinfections in Healthy Seroimmune WomenThe Journal of Infectious Diseases, 2010
- How we treat cytomegalovirus in hematopoietic cell transplant recipientsBlood, 2009
- Vaccine Prevention of Maternal Cytomegalovirus InfectionNew England Journal of Medicine, 2009
- Valacyclovir Prophylaxis Versus Preemptive Valganciclovir Therapy to Prevent Cytomegalovirus Disease After Renal TransplantationAmerican Journal of Transplantation, 2008
- Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlersThe Pediatric Infectious Disease Journal, 2002
- Effects of Antigen Dose and Immunization Regimens on Antibody Responses to a Cytomegalovirus Glycoprotein B Subunit VaccineThe Journal of Infectious Diseases, 1999
- A Subunit Cytomegalovirus Vaccine Based on Recombinant Envelope Glycoprotein B and a New AdjuvantThe Journal of Infectious Diseases, 1999
- MULTICENTER TRIAL OF TOWNE STRAIN ATTENUATED VIRUS VACCINE IN SERONEGATIVE RENAL TRANSPLANT RECIPIENTSTransplantation, 1994
- SYMPTOMATIC CYTOMEGALOVIRUS INFECTION IN SEROPOSITIVE KIDNEY RECIPIENTS: REINFECTION WITH DONOR VIRUS RATHER THAN REACTIVATION OF RECIPIENT VIRUSThe Lancet, 1988